Trial intelligence / Profile preview

Isatuximab + pomalidomide + dexamethasone in relapsed multiple myeloma after lenalidomide + proteasome inhibitor

2024-516060-28-00Phase 2Authorised

Sponsor: Hellenic Society of Hematology
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Overall response rate (ORR) at 6 months. Planned start Nov 2024; status: authorised.

Drugs

isatuximab

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2024-516060-28-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516060-28-00.